 
                    
                CHA Vaccine Research Institute
Develops vaccines and immunotherapies for infectious diseases and cancer using proprietary platforms.
261780 | KO
Overview
Corporate Details
- ISIN(s):
- KR7261780001
- LEI:
- Country:
- South Korea
- Address:
- 경기도 성남시 중원구 둔촌대로 560, 406,407호(상대원동, 벽산테크노피아), 성남시
- Website:
- http://en.chavaccine.com/
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
CHA Vaccine Research Institute is a clinical-stage biotechnology company specializing in the development of therapeutic and prophylactic vaccines and immunotherapeutics. A member of the CHA Medical and Bio Group, the company focuses on preventing and treating infectious diseases and cancer. Its core pipeline includes a third-generation hepatitis B (HBV) vaccine, a therapeutic vaccine for chronic HBV, a recombinant zoster (shingles) vaccine, and an improved influenza vaccine. The company leverages proprietary immune adjuvant platform technologies, such as L-pampo, and its own messenger RNA (mRNA) delivery system to enhance vaccine efficacy.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2025-09-01 00:00 | Major Shareholding Notification 주식등의대량보유상황보고서(일반) | Korean | 103.5 KB | ||
| 2025-08-25 00:00 | Post-Annual General Meeting Information 임시주주총회결과               | Korean | 7.1 KB | ||
| 2025-08-25 00:00 | Board/Management Information 대표이사변경               | Korean | 8.9 KB | ||
| 2025-08-13 00:00 | Interim Report 반기보고서 (2025.06) | Korean | 1.0 MB | ||
| 2025-08-08 00:00 | Pre-Annual General Meeting Information 주주총회소집공고 | Korean | 53.2 KB | ||
| 2025-07-15 00:00 | Pre-Annual General Meeting Information 주주명부폐쇄기간또는기준일설정               | Korean | 4.3 KB | ||
| 2025-07-15 00:00 | Pre-Annual General Meeting Information 주주총회소집결의              (임시주주총회) | Korean | 8.0 KB | ||
| 2025-07-08 00:00 | Legal Proceedings Report 투자판단관련주요경영사항(임상시험결과)              (재조합 대상포진 백신(CVI-VZV-001)의 제 1상 임상시험 결과보고서 수령) | Korean | 29.2 KB | ||
| 2025-06-25 00:00 | Report Publication Announcement 기업설명회(IR)개최               | Korean | 7.0 KB | ||
| 2025-06-20 00:00 | Regulatory News Service 투자판단관련주요경영사항(임상시험결과)              (만성B형간염 치료백신 CVI-HBV-002의 2b상 임상시험 결과보고서 수령) | Korean | 13.8 KB | ||
| 2025-05-14 00:00 | Quarterly Report 분기보고서 (2025.03) | Korean | 1007.7 KB | ||
| 2025-04-18 00:00 | Legal Proceedings Report 투자판단관련주요경영사항(임상시험결과)              (재조합 대상포진 백신(CVI-VZV-001)의 제 1상 임상시험 Topline … | Korean | 22.7 KB | ||
| 2025-04-09 00:00 | Major Shareholding Notification 임원ㆍ주요주주특정증권등소유상황보고서 | Korean | 23.7 KB | ||
| 2025-03-26 00:00 | Board/Management Information 사외이사의선임ㆍ해임또는중도퇴임에관한신고 | Korean | 10.4 KB | ||
| 2025-03-26 00:00 | Post-Annual General Meeting Information 정기주주총회결과               | Korean | 27.9 KB | 
Automate Your Workflow. Get a real-time feed of all CHA Vaccine Research Institute filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for CHA Vaccine Research Institute
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for CHA Vaccine Research Institute via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value | 
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
 
                                        
                                     
                                        
                                     
                                        
                                     
                                        
                                     
                                        
                                     
                                        
                                     
                                        
                                     
                                        
                                    